At the beginning of December last year, we took an in-depth look at the Canadian biotech company XPhyto Therapeutics. The in-depth report looked at the three divisions - Diagnostics, Innovative Dosage Forms and Psychedelics - and put the business in the context of the overall market. In the meantime, a lot has happened at XPhyto: the Company has published an update on the individual business areas and announced news around its activities in rapid PCR-quality corona tests. Reason enough for an update.Den vollständigen Artikel lesen ...
© 2022 researchanalyst.com (EN)